Agenus to Provide Corporate Update and First Quarter 2022 Financial Report
April 26 2022 - 8:30AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, adjuvants, and vaccines designed
to activate immune response to cancers and infections, today
announced it will release its first quarter 2022 financial results
before the market opens on Tuesday, May 10, 2022. Agenus executives
will host a conference call and webcast at 8:30 a.m. ET the same
day to discuss the results and to provide a corporate update.
Conference CallDial-in numbers: (866) 374-5140
(US Toll-Free) or (404) 400-0571 (US Toll)Conference PIN:
71044045#
WebcastA live webcast and replay of the
conference call will be accessible from the Events &
Presentations page of the Company’s website at
https://investor.agenusbio.com/events-and-presentations and via
https://edge.media-server.com/mmc/p/5nove2tf.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its subsidiary MiNK Therapeutics), adjuvants,
and proprietary cancer vaccine platforms. The Company is equipped
with a suite of antibody discovery platforms and a state-of-the-art
GMP manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to our technologies, therapeutic candidates,
and capabilities. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
ContactAgenus Inc.Ethan
Lovell339-927-1763ethan.lovell@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024